U.S. FDA approves Amgen leukemia drug ahead of schedule

U.S. health regulators on Wednesday approved an Amgen Inc drug that helps the immune system fight a rare type of leukemia, more than five months ahead of the expected decision date. The drug, blinatumomab, which will be sold under the brand name Blincyto, was approved to treat a form of acute lymphoblastic leukemia for which there are few treatment options once a patient has relapsed.

http://ift.tt/1vNcls1